The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Yajing Chen Biography and Net Worth

CFO of Zai Lab

Dr. Chen is a seasoned finance executive and leader with more than 20 years of experience in the life sciences industry as well as a Ph.D. trained scientist. Dr. Chen’s scientific background combined with her significant executive management experience, finance expertise at leading global companies, and business acumen allow her to bring a unique perspective to Zai Lab.

Dr. Chen was promoted to the position of Chief Financial Officer in July 2023. She previously served as the Company’s Senior Vice President and Deputy Chief Financial Officer since September 2021. Dr. Chen joined the Company from AstraZeneca where she held various roles of increasing responsibility from 2006 to 2021, including Chief Financial Officer for the U.S. Oncology Business Unit from 2019 to 2021 and Finance Controller of the Global Oncology Business Unit from 2016 to 2019. In these roles, Dr. Chen led financial planning and analysis as well as the development of a long-term strategic plan for the oncology therapy area, guiding business development, pipeline prioritization, and commercial strategy and enabling substantial revenue growth for their global oncology business.

Dr. Chen earned a Ph.D. in Microbiology from New York University and an MBA from Columbia University.

What is Yajing Chen's net worth?: The estimated net worth of Yajing Chen is at least $153,022.38 as of April 4th, 2024. Dr. Chen owns 9,618 shares of Zai Lab stock worth more than $153,022 as of April 28th. This net worth evaluation does not reflect any other assets that Dr. Chen may own. Learn More about Yajing Chen's net worth.
How do I contact Yajing Chen?: The corporate mailing address for Dr. Chen and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on Yajing Chen's contact information.
Has Yajing Chen been buying or selling shares of Zai Lab?: In the last ninety days, Yajing Chen has sold $21,623.00 of Zai Lab stock. Most recently, Yajing Chen sold 845 shares of the business's stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a transaction totalling $13,241.15. Following the completion of the sale, the chief financial officer now directly owns 9,618 shares of the company's stock, valued at $150,714.06. Learn More on Yajing Chen's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 2 times. They purchased a total of 9,000 shares worth more than $254,250.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 40,476 shares worth more than $940,803.05. The most recent insider tranaction occured on April, 4th when insider Joshua L Smiley sold 1,988 shares worth more than $31,151.96. Insiders at Zai Lab own 5.2% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 4/4/2024.

Yajing Chen Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2024	Sell	845	$15.67	$13,241.15	9,618
4/2/2024	Sell	519	$16.15	$8,381.85	7,963
11/2/2023	Sell	165	$25.23	$4,162.95	6,982

Yajing Chen Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $15.91

$15.65

$16.05

50 Day Range

MA: $17.45

$13.72

$22.49

2 Week Range

Now: $15.91

$13.48

$39.50

Volume

364,581 shs

Average Volume

470,952 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

See how you can invest alongside him